Boston Oncology and King Fahd Medical City (KFMC) Partner to Advance Localized Cell & Gene Therapy in Saudi Arabia
In a landmark initiative poised to transform healthcare in the Kingdom of Saudi Arabia, Boston Oncology and King Fahd Medical City (KFMC) have signed a Letter of Intent to collaborate on the localization of Cell & Gene Therapy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731424463/en/
Representatives from Boston Oncology and King Fahd Medical City (KFMC), along with His Excellency Eng. Abdulaziz AlRamaih, Deputy Minister of Health for Planning and Development, at the signing ceremony for the partnership to advance localized Cell & Gene Therapy in Saudi Arabia. (Photo: Business Wire)
The signing ceremony, attended by His Excellency Eng. Abdulaziz AlRamaih, Deputy Minister of Health for Planning and Development, marks a significant step forward in advancing the Kingdom’s medical capabilities and achieving the ambitious goals set forth in Vision 2030.
A Milestone in Healthcare Transformation
Dr. Fahad Al-Ghofaili, KFMC CEO, expressed his enthusiasm: “Localizing Cell & Gene Therapy in KFMC is an important step to increase local capabilities in advanced treatments and medical technologies, contributing to the goals of the Healthcare Transformation Project.” [Translated from Arabic]
Impact for Patients
Boston Oncology, renowned for its customer-centered model, brings extensive expertise in localizing technology. Laser-focused on the real-world needs of patients and hospitals, Boston Oncology is positioned to provide cutting-edge technologies and Cell & Gene Therapies through this partnership. This collaboration will establish a local treatment option, relieving bottlenecks in therapy provision and improving patient outcomes. The resulting Research & Development and clinical trials will significantly contribute to innovative advancements in the healthcare sector of Saudi Arabia.
Dr. Abdullah Baaj, CEO of Boston Oncology, described the partnership: “KFMC brings world-class clinicians and infrastructure, making it a destination for patients throughout the region. Joining forces to localize Cell & Gene Therapy is a transformative step towards our mission to impact the lives of one billion patients.”
About Boston Oncology Cell & Gene Therapy
Boston Oncology is an innovative life science company with a mission to impact the lives of one billion patients by 2030. With corporate headquarters in Cambridge, Massachusetts, and operations throughout the world, the company is focused on bringing patient-centered solutions and advanced treatment modalities to growing markets. Its new Cell & Gene Therapy entity establishes a fully localized offering to deliver personalized treatments that address the unique genetic profiles of patients. By partnering with leading medical institutions and leveraging leading-edge technologies, Boston Oncology CGT is expanding the company’s legacy of transformative advancements in healthcare.
Learn more at https://bostononcology.com/.
About King Fahd Medical City
King Fahad Medical City (KFMC) in Riyadh, Saudi Arabia, stands as one of the largest and most rapidly expanding medical complexes in the Middle East, with a capacity of 1,200 beds. Operating within the second health cluster, KFMC consists of four hospitals and four specialized medical centers, offering comprehensive healthcare services. Known for its advanced medical technologies and high standard of care, KFMC serves over 30,000 inpatients and 500,000 outpatients annually. The institution is committed to excellence in clinical services, medical education, research, and continuous improvement in healthcare.
Learn more at https://www.kfmc.med.sa/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731424463/en/
Contacts
Boston Oncology Public Relations:
bo_cgt@bostononcology.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Multiply Group Lights up the World With the Launch of Multiply Media Group, Creating a Media Powerhouse Headquartered in the UAE6.6.2025 13:52:00 EEST | Press release
Multiply Group (ADX: MULTIPLY), the Abu Dhabi-based investment holding company, today launches Multiply Media Group (MMG), uniting the three market-leading out-of-home (OOH) companies under its portfolio to create a new media powerhouse headquartered in the UAE. The combination of BackLite Media, Viola Media and Media 247 under Multiply Media Group represents a significant move that will shape the future of tech-enabled media in the UAE and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606708480/en/ Multiply Group lights up the world with the launch of Multiply Media Group, creating a media powerhouse headquartered in the UAE (Photo: AETOSWire) Samia Bouazza, GCEO and Managing Director of Multiply Group, said: “The launch of Multiply Media Group represents the most significant media consolidations in the UAE. By bringing together market-leading media assets under a single AI & tech-driven group, we are reinforcin
TVS Motor Announces Sudarshan Venu as Chairman of the Company Effective August 25, 20256.6.2025 13:31:00 EEST | Press release
TVS Motor Company announced today that The Board of Directors unanimously named Mr Sudarshan Venu as incoming Chairman of the Company, in recognition of his exemplary contributions to the Company’s sustained growth and strategic development during his tenure as Director. Effective August 25, 2025, Mr Sudarshan Venu will be appointed as Chairman and Managing Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606441596/en/ Sudarshan Venu, Managing Director, TVS Motor Company. Its current chairman, Sir Ralf Speth, has informed The Board of Directors that he will not be seeking re-appointment as a company Director at the upcoming Annual General Meeting (AGM). Consequently, he will step down as Chairman of the Company at the close of the AGM on August 22, 2025. The Board will also be appointing Sir Ralf Speth as Chief Mentor of the Company for a period of three years effective August 23, 2025, ensuring continued benefit
Budweiser Kicks Off New “Celebration in the Making” Global Platform for FIFA Club World Cup 2025™6.6.2025 11:00:00 EEST | Press release
Today, Budweiser (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD) unveils its new global platform “Celebration in the Making” and full campaign details as the Official Global Beer Sponsor of the FIFA Club World Cup 2025™. This summer, as football supporters around the globe bring their energy to the groundbreaking tournament, Budweiser will be there to elevate celebrations at every stage – from the opening touch to the final whistle, and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606379419/en/ Budweiser Kicks Off New “Celebration in the Making” Global Platform for FIFA Club World Cup 2025™ To inspire celebrations from the start, Budweiser is officially kicking off the platform with a new film set to an iconic score, and announces the return of its acclaimed “Bring Home The Bud” campaign to deliver the ultimate prize of free beer for the winning club* and its supporters. Budweiser will also leverage exclusive FIFA-
SES Announces Appointment of New CFO6.6.2025 09:30:00 EEST | Press release
SES today announced its Board of Directors has appointed Elisabeth (Lisa) Pataki as Chief Financial Officer (CFO), effective 16 June 2025. Lisa is a progressive finance executive with over 20 years of experience at various publicly listed multi-national aerospace and defence companies with strong background in company transformation and investment strategies. She will succeed Sandeep Jalan who has been SES’s CFO since May 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250605243814/en/ Lisa Pataki The SES Board acknowledges Sandeep’s contribution to SES and wishes him success in future endeavours. Lisa will work closely with Sandeep to ensure a smooth handover before he leaves on 31 July 2025. “I would like to thank Sandeep for his steadfast leadership over the last five years where he has driven continuous execution improvement and transformation while strengthening the company’s balance sheet with a competitive cost o
RAD 2025: Long-Term Data on Nemluvio ® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years6.6.2025 08:00:00 EEST | Press release
Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio in moderate-to-severe atopic dermatitis. The data show that Nemluvio is well tolerated, with no new safety signals identified, reinforcing its rapid onset of action and demonstrating sustained and increased improvements in symptoms including itch and skin lesions with prolonged treatment up to two years.1 These data will be presented in a late-breaker abstract at the Revolutionizing Atopic Dermatitis (RAD) Conference, taking place from June 6-7, 2025. “With Nemluvio now being launched in several countries, it’s so encouraging that we continue to see its robust evidence base expand. Long-term data is pivotal to this, highlighting the profound impact this innovative treatment can have in atopic dermatitis well into the future.” BALDO SCASSELLATI SFORZOLINI, M.D., PHD. GLOBAL HEAD OF RESEARCH & DEVELOPMENT GALDERMA Atopic dermatiti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom